PERSPECTIVE THERAPEUTICS Business Summary

Perspective Therapeutics Inc. (CATX) operates as a clinical-stage radiopharmaceutical company specializing in the development of precision targeted alpha therapies (TAT) and diagnostic imaging. The company generates revenue through two primary business segments: its legacy brachytherapy business, which sells Cesium-131 seeds for localized cancer treatment, and its high-growth radiopharmaceutical pipeline focused on the alpha-emitting isotope Lead-212 (212Pb). Its business model is centered on a "theranostic" approach, utilizing proprietary targeting peptides to first image tumors and then deliver potent alpha-particle radiation to destroy cancer cells with high precision. Direct competitors include Lantheus Holdings (LNTH), Actinium Pharmaceuticals (ATNM), and Telix Pharmaceuticals (TLX). Perspective differentiates itself by leveraging its proprietary 212Pb generator and chelator technology, positioning the company as a specialized leader in the emerging TAT market relative to larger incumbents focused on beta-emitting isotopes. The leadership team is led by CEO Thijs Spoor, an experienced healthcare executive with a background in nuclear medicine and capital markets, and CFO Joel David Sendek, who brings extensive experience in biotechnology financial management. The company’s scientific foundation is anchored by Co-Founder and Chief Science Officer Dr. Michael K. Schultz, a pioneer in radiopharmaceutical chemistry, alongside Chief Medical Officer Dr. Markus Puhlmann, who oversees the clinical advancement of lead candidates VMT-α-NET and VMT01. The Board of Directors is chaired by Lori Holmes-Woods and includes industry veterans such as Robert Williamson and Maya Martinez-Davis. Notable institutional backing includes strategic investor Lantheus Holdings, as well as TCG Crossover, Avidity Partners, and Patient Square Capital, reflecting strong market confidence in the company’s Lead-212 platform.